R
Robert Brunell
Researcher at Pfizer
Publications - 5
Citations - 675
Robert Brunell is an academic researcher from Pfizer. The author has contributed to research in topics: Placebo & Bococizumab. The author has an hindex of 5, co-authored 5 publications receiving 585 citations. Previous affiliations of Robert Brunell include University of Zaragoza.
Papers
More filters
Journal ArticleDOI
Cardiovascular efficacy and safety of bococizumab in high-risk patients
Paul M. Ridker,James H. Revkin,Pierre Amarenco,Robert Brunell,Madelyn Curto,Fernando Civeira,Marcus Flather,Robert J. Glynn,Jean Gregoire,J. Wouter Jukema,Yuri Karpov,John J.P. Kastelein,Wolfgang Koenig,Alberto J. Lorenzatti,Pravin Manga,Urszula Masiukiewicz,Michael Miller,Arend Mosterd,Jan Murin,Jose C. Nicolau,Steven E. Nissen,Piotr Ponikowski,Raul D. Santos,Pamela F. Schwartz,Handrean Soran,Harvey D. White,R. Scott Wright,Michal Vrablík,Carla Yunis,Charles L. Shear,Jean-Claude Tardif +30 more
TL;DR: In two randomized trials comparing the PCSK9 inhibitor bococizumab with placebo, bococzumab had no benefit with respect to major adverse cardiovascular events in the trial involving lower‐risk patients but did have a significant benefit in the Trial involving higher‐risk Patients.
Journal ArticleDOI
A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee
Marie-Pierre Hellio Le Graverand,R. Clemmer,Patricia Redifer,Robert Brunell,Curtis W. Hayes,Kenneth D. Brandt,Steven B. Abramson,Pamela T Manning,Colin G. Miller,Eric Vignon +9 more
TL;DR: Cindunistat (50 or 200 mg/day) did not improve joint pain or function, but was generally well tolerated and iNOS inhibition did not slow OA progression in KLG3 patients.
Journal ArticleDOI
Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials
Paul M. Ridker,Pierre Amarenco,Robert Brunell,Robert J. Glynn,J. Wouter Jukema,John J.P. Kastelein,Wolfgang Koenig,Steven E. Nissen,James H. Revkin,Raul D. Santos,Pamela F. Schwartz,Carla Yunis,Jean-Claude Tardif +12 more
TL;DR: The SPIRE trial as mentioned in this paper evaluated the efficacy and safety of bococizumab in the prevention of incident vascular events in high-risk populations with and without clinically evident cardiovascular disease.
Journal ArticleDOI
Considerations when designing a disease-modifying osteoarthritis drug (DMOAD) trial using radiography.
Marie-Pierre Hellio Le Graverand,R. Clemmer,Robert Brunell,Curtis W. Hayes,Colin G. Miller,Eric Vignon +5 more
TL;DR: Using a tightly controlled radiographic technique, JSN is a viable outcome variable for determining disease progression in mild-to-moderate knee OA and is a sensitive and feasible method for OA studies aiming to assess rate of JSN in the knee.
Journal ArticleDOI
A 2-year randomized, double-blind, placebo-controlled, multicenter study of an oral selective iNOS inhibitor in subjects with symptomatic osteoarthritis of the knee
M.-P. Hellio Le Graverand-Gastineau,R. Clemmer,P. Redifer,Robert Brunell,Curtis W. Hayes,Kenneth D. Brandt,Steven B. Abramson,Pamela T. Manning,Colin G. Miller,Eric Vignon +9 more